Jaguar Health (JAGX) Total Non-Current Liabilities (2014 - 2026)
Jaguar Health's (JAGX) quarterly Total Non-Current Liabilities came in at $53.0 million in Q1 2026, up 375.84% year-on-year from $11.1 million in Q1 2025, and up 111.07% on a QoQ basis from $25.1 million in Q4 2025.
Jaguar Health (JAGX) Total Non-Current Liabilities (2014 - 2026) Analysis & Trends
Jaguar Health (JAGX) has 13 years of Total Non-Current Liabilities data on file, last reported at $53.0 million in Q1 2026.
- On a quarterly basis, Total Non-Current Liabilities rose 375.84% year-over-year to $53.0 million in Q1 2026; TTM through Mar 2026 was $53.0 million, a 375.84% increase from a year earlier, with the FY2025 full-year figure at $25.1 million, up 176.24% from the prior year.
- Total Non-Current Liabilities for Q1 2026 stood at $53.0 million, up from $25.1 million in the prior quarter.
- Over the last five years, Total Non-Current Liabilities for JAGX reached as high as $53.0 million in Q1 2026 and fell as low as $9.1 million in Q4 2024.
- Historically, Total Non-Current Liabilities has averaged $22.3 million across 5 years, with a median of $14.7 million in 2025.
- Across the five-year window, Total Non-Current Liabilities sank 63.57% in 2023 and jumped 375.84% in 2026, its largest moves.
- Year by year, Total Non-Current Liabilities stood at $41.0 million in 2022, then sank by 63.57% to $14.9 million in 2023, then slumped by 39.09% to $9.1 million in 2024, then soared by 176.24% to $25.1 million in 2025, then surged by 111.07% to $53.0 million in 2026.
- Per Business Quant data, the three most recent Total Non-Current Liabilities figures were $53.0 million in Q1 2026, $25.1 million in Q4 2025, and $14.7 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Nanobiotix | 1,782.24 Bn | 1,782.18 Bn | - | 107.80 Mn |
| 2 | Akari Therapeutics | 1,009.43 Bn | 1,009.43 Bn | - | 19.49 Mn |
| 3 | BeOne Medicines | 473.46 Bn | 468.66 Bn | 1.35 Bn | 1.98 Bn |
| 4 | Vertex Pharmaceuticals | 123.84 Bn | 116.59 Bn | 2.59 Bn | 5.87 Bn |
| 5 | Regeneron Pharmaceuticals | 71.69 Bn | 62.94 Bn | 3.31 Bn | 7.32 Bn |
| 6 | Belite Bio | 62.15 Bn | 62.15 Bn | - | - |
| 7 | Argenx Se | 54.74 Bn | 49.55 Bn | 1.41 Bn | 40.00 Mn |
| 8 | Alnylam Pharmaceuticals | 38.08 Bn | 35.07 Bn | 959.66 Mn | 4.05 Bn |
| 9 | Revolution Medicines | 36.07 Bn | 36.07 Bn | - | 746.94 Mn |
| 10 | Jaguar Health | 520,945.88 | -9.54 Mn | 19.11 Mn | 53.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 53.00 Mn |
| Dec 31, 2025 | 25.11 Mn |
| Sep 30, 2025 | 14.69 Mn |
| Jun 30, 2025 | 12.58 Mn |
| Mar 31, 2025 | 11.14 Mn |
| Dec 31, 2024 | 9.09 Mn |
| Sep 30, 2024 | 10.09 Mn |
| Mar 31, 2024 | 9.13 Mn |
| Dec 31, 2023 | 14.92 Mn |
| Dec 31, 2022 | 40.97 Mn |
| Mar 31, 2022 | 44.80 Mn |
| Dec 31, 2021 | 41.41 Mn |
| Sep 30, 2021 | 37.70 Mn |
| Jun 30, 2021 | 37.75 Mn |
| Mar 31, 2021 | 36.81 Mn |
| Dec 31, 2020 | 25.64 Mn |
| Sep 30, 2020 | 28.30 Mn |
| Jun 30, 2020 | 21.07 Mn |
| Mar 31, 2020 | 15.42 Mn |
| Dec 31, 2019 | 14.34 Mn |